Virax Biolabs Group Limited (NASDAQ: VRAX) is a UK-headquartered biotechnology company focused on immunology and diagnostics, developing the ViraxImmune T-cell profiling platform for post-acute infection syndromes such as long COVID. It is a micro-cap with only one materially active covering firm, H.C. Wainwright & Co., whose analyst Yi Chen maintains a Buy rating with a $1.00 price target.
Because a single analyst does not constitute a consensus, the $1.00 figure is best understood as the most recently published sell-side target rather than an average analyst price target. The picture is further complicated by the company's 1-for-25 share consolidation completed in June 2026: some data providers display the same H.C. Wainwright view as $25.00, while others show $1.00. Against a current price near $0.79, the $1.00 reading implies roughly 27% upside, which is why it is used here as the central objective.
In early November 2026, VRAX shares closed near $0.79, with a 52-week range of approximately $0.63 to $21.75 and a market capitalization of roughly $1 million. Reaching $1.00 would require a gain of about 27%, a substantial move for a stock trading at the lower end of its range after a prolonged decline.
Notably, the company reported roughly $6.4 million in cash on its fiscal 2026 balance sheet against a market value of about $1 million, implying a negative enterprise value (EV) and a price-to-book ratio far below 1. In theory, this creates an unusually low valuation floor; in practice, it also reflects investor skepticism that the cash will be preserved amid ongoing losses. The path toward $1.00 therefore depends less on near-term profitability than on demonstrating commercial progress before the cash runway is consumed.
The stock sits near the bottom of its 52-week range, with recent intraday support near $0.63 and a 52-week high around $21.75. The $1.00 target coincides roughly with a round-number psychological level and would require clearing the steep downtrend that has dragged the price well below its 200-day moving average. A sustained move above $1.00 would likely require a meaningful shift in volume and sentiment, not merely a short-term bounce.
A single-analyst price target typically reflects a roughly 12-month research horizon, but no explicit timeline accompanies the H.C. Wainwright view, and a micro-cap with this volatility can deviate sharply from any horizon. Investors should watch quarterly results and cash burn, updates on the ImmuneSelect distribution rollout and Fosun agreement, further ViraxImmune clinical data, any new financing or dilution, and whether the share price can hold above the $0.63 support zone.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a highly volatile micro-cap like VRAX, this kind of automated monitoring can help traders spot changing momentum and manage positions more efficiently than manual scanning. Traders can use the tool to discover opportunities, track existing positions, and react to emerging trends with less guesswork.
The question of whether VRAX can reach $1.00 hinges on an unusual contrast: a market capitalization far below the company's cash balance, set against minimal revenue and persistent losses. The most recently published sell-side target of $1.00 implies roughly 27% upside and is plausible in absolute terms, but it reflects a single analyst's view rather than a broad consensus, and the reverse-split-adjusted data across providers is inconsistent. Balance-sheet strength and early commercial and clinical momentum are the main supports, while negligible revenue, dilution, and micro-cap volatility are the principal obstacles. Investors should monitor cash runway, commercial execution, and price stability above $0.63 rather than treat the target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VRAX has been loosely correlated with ALZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRAX jumps, then ALZN could also see price increases.
| Ticker / NAME | Correlation To VRAX | 1D Price Change % | ||
|---|---|---|---|---|
| VRAX | 100% | -9.27% | ||
| ALZN - VRAX | 45% Loosely correlated | -5.92% | ||
| NTRB - VRAX | 31% Poorly correlated | -3.36% | ||
| PTGX - VRAX | 30% Poorly correlated | +0.26% | ||
| CAPR - VRAX | 30% Poorly correlated | -9.95% | ||
| DYAI - VRAX | 29% Poorly correlated | -3.84% | ||
More | ||||